Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental Weight-Loss drug AMG 133 put to the test in formulation showdown

NCT ID NCT07717814

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 1 trial compares how well three different versions of the experimental drug AMG 133 (maridebart cafraglutide) are absorbed after a single injection in people with overweight or obesity. The study involves 154 adults aged 18 to 65 with a body mass index between 25 and 40. Researchers will measure drug levels in the blood and monitor for side effects to determine which formulation works best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called AMG 133 (maridebart cafraglutide)
What this could lead to
If successful, this study could help determine the best way to deliver AMG 133 for future weight-loss treatments.
What could go wrong
This is an early phase 1 trial focused on drug absorption, not on weight loss or safety. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY

Contacts and locations

Locations

  • Anaheim Clinical Trials

    Anaheim, California, 92801, United States

  • Fortrea Clinical Research Unit - Dallas

    Dallas, Texas, 75247, United States

  • Fortrea Clinical Research Unit - Daytona Beach

    Daytona Beach, Florida, 32117-5116, United States

  • Fortrea Clinical Research Unit Inc. - Madison

    Madison, Wisconsin, 53704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.